---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-088454"
form_type: "8-K"
ticker: null
cik: "0001538210"
company_name: "NexImmune, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:47:48.670351+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NexImmune CFO Timothy Stover resigns; Albert Marchio named interim CFO

## Summary
- Timothy Stover, principal financial and accounting officer, resigns effective April 16, 2024; not due to disagreement.
- Albert N. Marchio II appointed Interim CFO and principal financial/accounting officer, effective upon Stover's resignation.
- Marchio, 71, has 32 years pharma industry experience; currently a consultant via Danforth Advisors LLC.
- Danforth Advisors will provide interim CFO services under a consulting agreement with hourly rate and indemnification terms.

## SEC filing metadata
- accession: 0001193125-24-088454
- form_type: 8-K
- cik: 0001538210
- company_name: NexImmune, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/d818104d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-088454
- JSON: https://secwatch.observer/filing/0001193125-24-088454.json
- Plain text: https://secwatch.observer/filing/0001193125-24-088454.txt

## Key facts
- Executive change
  Albert N. Marchio II was appointed as Interim Chief Financial Officer at NexImmune, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On April 5, 2024, the Board of Directors of the Company appointed Albert N. Marchio II as Interim Chief Financial Officer and designated him to serve as the principal financial officer and principal accounting officer of the Company effective upon Mr. Stover’s resignation (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm
- Executive change
  Timothy Stover resigned as Vice President, Corporate Controller and principal financial officer and principal accounting officer at NexImmune, Inc..
  - Action: resigned
  - Role: Vice President, Corporate Controller and principal financial officer and principal accounting officer
  source text: On April 1, 2024, Timothy Stover, Vice President, Corporate Controller and the principal financial officer and principal accounting officer of NexImmune, Inc. (the “Company”), notified the Company of his intention to resign from all positions he holds at the Company, effective on April 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000119312524088454/0001193125-24-088454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.